Volume 18, Number 11—November 2012
Severe Pneumonia Caused by Legionella pneumophila Serogroup 11, Italy
To the Editor: Legionella pneumophila serogroups (SGs) 1–16 cause pneumonia in humans. Although SG 1 is the serogroup most commonly associated with disease (1), we report a case of community-acquired legionellosis caused by SG 11.
In November 2010, a 42-year-old man was admitted to Modena University Hospital, Modena, Italy, with a 4-day history of fever, dyspnea, and cough. His vital signs were as follows: temperature 40.0°C, pulse 135 beats/min, blood pressure 110/60 mm Hg, respiratory rate 30 breaths/min, and oxygen saturation 85% in room air. Inspiratory crackles were heard in the left lower lung lobe. Chest radiographs and successive high-resolution computerized tomography revealed left lobar infiltrates (Figure, panels A and B). Blood count documented severe pancytopenia together with high levels of inflammation markers: fibrinogen (1,031 mg/dL), C-reactive protein (33 mg/dL), and procalcitonin (28.5 ng/mL). The patient’s medical history was unremarkable; however, results of tests conducted at the time of hospital admission led to the diagnosis of acute leukemia.
Empirically prescribed antimicrobial treatment for neutropenic patients was initiated and consisted of meropenem (3 g/day) and levofloxacin (500 mg/day), combined first with vancomycin (2 g/day) and later with linezolid (1,200 mg/day). A few days later, antifungal therapy was empirically added to the treatment regimen (liposomal amphotericin B at 3 mg/kg/day). The patient received continuous positive airway pressure, which resulted in progressive improvement of blood gas exchange, until normalization was achieved.
Serologic and molecular examination and culture of bronchoalveolar lavage fluid, blood, urine, and feces produced negative results for fungal, viral, and bacterial pathogens. Test results for L. pneumophila urinary antigen (Biotest AG, Dreieich, Germany) and IgM and IgG against L. pneumophila (Serion-Immundiagnostica GmbH, Würzburg, Germany) were negative. Culture of sputum collected at the time of hospital admission showed growth of legionella-like colonies on buffered charcoal yeast extract, with and without the addition of antimicrobial drugs (Oxoid, Basingstoke, UK). The colonies were identified as L. pneumophila SGs 2–14 by the Legionella latex test (Oxoid). The strain was further characterized as L. pneumophila SG 11, according to a polyclonal latex reagent set (Biolife, Milan, Italy). Environmental investigations were conducted in the patient’s house and workplace, but L. pneumophila SG 11 was not detected in any of the locations tested.
A week after hospital admission, the patient was persistently febrile and experienced pain in the left thorax. High-resolution computerized tomography of the chest was repeated and showed increased pulmonary infiltrate (Figure, panels C and D) that was consistent with L. pneumophila pneumonia (2). Highly potent antimicrobial therapy against L. pneumophila was administered, consisting of high-dosage levofloxacin (1 g/day) combined with azithromycin (500 mg/day), while the other antimicrobial agents were progressively reduced (3). The fever subsided 14 days after the onset of targeted antimicrobial drug treatment; at that time, the sputum culture and test results for urinary L. pneumophila antigen were negative, but serologic assay results were positive for IgG and negative for IgM against L. pneumophila. Subsequent computerized tomographic scans of the chest documented progressive improvement of lung infiltrates, and nearly complete resolution was obtained 3 months after hospital admission.
L. pneumophila SG 11 infection has, thus far, been reported only rarely in humans. The first SG 11 strain was isolated in the United States in 1982 from a patient with multiple myeloma (4). Since then, few other cases of SG 11 strains have been reported in Europe (5,6); it is conceivable that this strain is not as widely distributed and is less pathogenic than other SGs, especially SG 1. It can be argued that infections caused by SG 11 have been underdiagnosed. L. pneumophila SG 11 cannot be detected by Legionella urinary antigen or serologic tests, the assays most frequently used to diagnose legionellosis (7–9). The negative urinary antigen test result for this patient is consistent with a non–SG 1 infection. The single positive serologic result for IgG was probably caused by cross-reactivity because the commercial assay kit was designed to recognize only L. pneumophila SGs 1–7. Culture is the only useful diagnostic tool for identifying SGs. However, this tool is not always feasible because it requires specialized media and skills to identify the organism. In addition, sensitivity is low, depending on the severity of the disease and the availability of adequate respiratory specimens (9). Despite these limitations, culture is needed to detect all SGs of L. pneumophila, especially in immunocompromised patients, who are more susceptible to infections caused by strains of non–SG 1 L. pneumophila (10).
We thank Teresa Stocki and Massimo Mentasti for their technical expertise and Valeria Fantuzzi and Franco Narni, who took care of the patient. We are grateful to Alice Artioli for linguistic revision of the manuscript.
This work was supported by the National Health Service.
- Palusińska-Szysz M, Cendrowska-Pinkosz M. Pathogenicity of the family Legionellaceae. Arch Immunol Ther Exp (Warsz). 2009;57:279–90.
- Yu H, Higa F, Hibiya K, Furugen M, Sato Y, Shinzato T, Computed tomographic features of 23 sporadic cases with Legionella pneumophila pneumonia. Eur J Radiol. 2010;74:e73–8.
- Sabrià M, Pedro-Botet ML, Gòmez J, Roig J, Vilaseca B, Sopena N, ; Legionnaires Disease Therapy Group. Fluoroquinolones vs macrolides in the treatment of Legionnaires disease. Chest. 2005;128:1401–5.
- Thacker WL, Benson RF, Wilkinson HW, Ampel NM, Wing EJ, Steigerwalt AG, 11th serogroup of Legionella pneumophila isolated from a patient with fatal pneumonia. J Clin Microbiol. 1986;23:1146–7.
- Helbig JH, Bernander S, Castellani Pastoris M, Etienne J, Gaia V, Lauwers S, Pan-European study on culture-proven Legionnaires’ disease: distribution of Legionella pneumophila serogroups and monoclonal subgroups. Eur J Clin Microbiol Infect Dis. 2002;21:710–6.
- Wewalka G, Schmid D, Harrison TG, Uldum SA, Lück C. Cases of dual infections with different Legionella strains. Presented at the 26th meeting of the European Working Group for Legionella Infections (EWGLI); 2011 May 25–27; Vienna, Austria. Stockholm: EWGLI; 2011.
- European Centre for Disease Prevention and Control. Legionnaires’ disease in Europe 2009. Stockholm: The Centre; 2011. p. 9.
- Shimada T, Noguchi Y, Jackson JL, Miyashita J, Hayashino Y, Kamiya T, Systematic review and meta-analysis: urinary antigen tests for legionellosis. Chest. 2009;136:1576–85.
- Blyth CC, Adams DN, Chen SCA. Diagnostic and typing methods for investigating Legionella infection. N S W Public Health Bull. 2009;20:157–61.
- Jacobson KL, Miceli MH, Tarrand JJ, Kontoyiannis DP. Legionella pneumonia in cancer patients. Medicine (Baltimore). 2008;87:152–9.
- Figure. . . Imaging studies of 42-year-old man with severe pneumonia caused by Legionella pneumophila serogroup 11, showing lobar consolidation of the left lower lung lobe, with an air-bronchogram within the...
Suggested citation for this article: Grottola A, Forghieri F, Meacci M, Fabio A, Pozzi L, Marchegiano P, et al. Severe pneumonia caused by Legionella pneumophila serogroup 11 [letter]. Emerg Infect Dis [Internet]. 2012 Nov [date cited]. http://dx.doi.org/10.3201/eid1811.120216
Please use the form below to submit correspondence to the authors or contact them at the following address:
Antonella Grottola, Unit of Microbiology and Virology, Regional Reference Laboratory for Clinical Diagnosis of Legionellosis, University Hospital-Policlinico, Via del Pozzo71, 41124 Modena, Italy
Comment submitted successfully, thank you for your feedback.
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
- Page created: September 28, 2012
- Page last updated: September 28, 2012
- Page last reviewed: September 28, 2012
- Centers for Disease Control and Prevention,
National Center for Emerging and Zoonotic Infectious Diseases (NCEZID)
Office of the Director (OD)